Press releases

To stay up to date with our development, sign up for a subscription.

Subscribe

Sedana Medical establishes sales organization in Benelux

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has set up its own direct sales organization in Benelux, in line with the strategy of being represented in several European markets in order to have well-established net…

Sedana Medical receives approval for AnaConDa in Mexico

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has obtained market approval for AnaConDa in Mexico. Sedana Medical's Mexican distributor Goba will begin sales work in the next few months and in parallel Sedana will e…

Last patient included in Sedana Medical's pivotal IsoConDa study

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the last patient has now been included in the pivotal IsoConDa study. Thus, all 300 patients have been included and the study is expected to show top-line results during Q2 2020.

Sedana Medical adjusts and clarifies its long-term financial targets

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company will no longer communicate a profit target for the period until registration of IsoConDa in Europe. It also clarifies the sales target of SEK 500 million three years aft…

Sedana Medical’s nomination committee appointed

Non-regulatory

Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 28, 2019, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes t…

Sedana Medical is co-funding AnaConDa study on lung protection

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is co-financing the world's largest multicenter study with AnaConDa in France. The primary purpose of the study is to show that inhaled sedation with AnaConDa has lung p…

Sedana Medical's AnaConDa approved to be used in children

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company's medical device AnaConDa, for the administration of volatile anesthetics for sedation of mechanically ventilated intensive care patients, has received approval for use…

Sedana Medical enters India – signs Indian distributor

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced a distribution agreement with the Indian distributor Hansraj Nayyar Medical. Sales will commence in the fall and a registration process will start in parallel. Hansraj Nayyar has committ…

Sedana Medical enters China – signs with Chinese distributor

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced a 10-year exclusive distribution agreement with the Chinese distributor Kyuan Xinhai Medical, a subsidiary of partly state-owned Shanghai Pharma, the second largest life science company…

Bulletin from annual general meeting in Sedana Medical AB (publ)

Regulatory

Sedana Medical AB (publ) (the "Company") held its annual general meeting on 28 May 2019 in Stockholm. The meeting resolved in accordance with all of the board of directors' and nomination committee's resolution proposals. Complete information on each…

Progress in Japan

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the first patient in Japan has been treated with AnaConDa and that the registration work for IsoConDa in Japan has been initiated. The Japanese market potential is estimated at EUR…